Equities Analysts Offer Predictions for RLAY Q3 Earnings

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for Relay Therapeutics to a loss of $0.37 per share from $0.36, while maintaining a Buy rating and $29 price target.
• Relay Therapeutics recently reported a quarterly loss of $0.41 per share, missing the $0.39 consensus estimate, and revenue of $0.35 million versus expectations of $0.96 million.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and average price target of $25.92, although forecasts indicate the clinical-stage biotechnology company is expected to remain unprofitable through 2027.

Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2026 earnings per share estimates for Relay Therapeutics in a research note issued on Thursday, August 20th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.37) for the quarter, down from their previous forecast of ($0.36). HC Wainwright has a "Buy" rating and a $29.00 price objective on the stock. The consensus estimate for Relay Therapeutics' current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Relay Therapeutics' Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.57) EPS, Q1 2027 earnings at ($0.39) EPS, Q2 2027 earnings at ($0.40) EPS, Q3 2027 earnings at ($0.40) EPS and Q4 2027 earnings at ($0.41) EPS.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $0.96 million.

Other research analysts also recently issued research reports about the stock. Oppenheimer lifted their target price on shares of Relay Therapeutics from $14.00 to $18.00 and gave the stock an "outperform" rating in a report on Tuesday, April 28th. Wells Fargo & Company lifted their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the stock an "overweight" rating in a research note on Tuesday, April 28th. JPMorgan Chase & Co. boosted their price objective on Relay Therapeutics from $28.00 to $31.00 and gave the stock an "overweight" rating in a research report on Friday, August 14th. JonesTrading upgraded Relay Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, May 19th. Finally, Citizens Jmp lifted their price target on Relay Therapeutics from $21.00 to $26.00 and gave the stock a "market outperform" rating in a research report on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $25.92.

Relay Therapeutics Price Performance

NASDAQ:RLAY opened at $19.44 on Monday. The company's 50 day moving average is $18.86 and its 200-day moving average is $14.40. Relay Therapeutics has a 12 month low of $3.43 and a 12 month high of $21.27. The firm has a market cap of $4.26 billion, a price-to-earnings ratio of -12.38 and a beta of 1.69.

Institutional Trading of Relay Therapeutics

A number of hedge funds have recently modified their holdings of RLAY. Alphabet Inc. bought a new stake in shares of Relay Therapeutics in the 2nd quarter valued at approximately $26,382,000. California State Teachers Retirement System lifted its position in shares of Relay Therapeutics by 47.9% during the 1st quarter. California State Teachers Retirement System now owns 174,099 shares of the company's stock worth $1,732,000 after buying an additional 56,422 shares during the period. Persistent Asset Partners Ltd acquired a new stake in Relay Therapeutics in the 2nd quarter valued at $1,323,000. Bank of America Corp DE boosted its stake in Relay Therapeutics by 86.1% in the 1st quarter. Bank of America Corp DE now owns 1,937,695 shares of the company's stock valued at $19,280,000 after buying an additional 896,746 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in Relay Therapeutics in the 4th quarter valued at $1,203,000. Institutional investors own 96.98% of the company's stock.

Insider Activity at Relay Therapeutics

In other news, insider Peter Rahmer sold 50,000 shares of the company's stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $19.09, for a total transaction of $954,500.00. Following the completion of the transaction, the insider owned 225,857 shares of the company's stock, valued at approximately $4,311,610.13. This represents a 18.13% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sanjiv Patel sold 48,199 shares of the stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $19.58, for a total transaction of $943,736.42. Following the completion of the sale, the chief executive officer owned 615,898 shares of the company's stock, valued at approximately $12,059,282.84. The trade was a 7.26% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 409,639 shares of company stock worth $7,233,399. 5.04% of the stock is owned by company insiders.

Relay Therapeutics News Roundup

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated its Buy rating and $29 price target, implying substantial upside from the stock’s recent level near $19.44. The firm expects continued losses but provided quarterly 2026 and 2027 EPS forecasts ranging from $(0.37) to $(0.41). What is HC Wainwright's Forecast for RLAY FY2027 Earnings?
• Positive Sentiment: Zacks Research upgraded Relay Therapeutics from “Strong Sell” to “Hold,” reducing a significant negative rating overhang, although the revised view remains neutral rather than bullish. Zacks.com
• Neutral Sentiment: HC Wainwright’s projections call for FY2026 EPS of $(1.57), Q1 2027 EPS of $(0.39), Q2 2027 EPS of $(0.40), Q3 2027 EPS of $(0.40), and Q4 2027 EPS of $(0.41). The estimates indicate that Relay remains an unprofitable clinical-stage biotechnology company, with investors dependent on pipeline progress and future drug-development milestones.
• Negative Sentiment: HC Wainwright lowered its FY2026 EPS forecast from $(1.50) to $(1.57), reduced its Q3 2026 estimate from $(0.36) to $(0.37), and cut its Q4 2026 estimate from $(0.37) to $(0.38). These revisions point to slightly higher expected losses and may be contributing to the stock’s softer performance.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source